ProCE Banner Activity

MET-Targeted Therapies in Development: Tepotinib, Crizotinib, Savolitinib, and Combinations

Slideset Download
Download these slides for expert insights on MET-targeted therapies in development for MET-altered NSCLC, including tepotinib for METex14 mutation–positive disease.

Released: May 29, 2020

Expiration: May 28, 2021

No longer available for credit.

Share

Faculty

Karen L. Reckamp

Karen L. Reckamp, MD, MS

Associate Professor
Medical Oncology and Therapeutics Research
City of Hope Comprehensive Cancer Center
Duarte, California

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

This educational activity is supported by an independent grant from the Healthcare business of

Merck KGaA

Faculty Disclosure

Primary Author

Karen L. Reckamp, MD, MS

Associate Professor
Medical Oncology and Therapeutics Research
City of Hope Comprehensive Cancer Center
Duarte, California